Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Caris Life Sciences
MedTech
Caris Life Sciences ups IPO to raise $494M
The cancer testing company claimed a valuation of about $5.9 billion, while selling 23.5 million shares under the Nasdaq ticker "CAI" at $21 apiece.
Conor Hale
Jun 18, 2025 11:00am
Caris Life Sciences to go public in $400M Nasdaq IPO
Jun 9, 2025 10:30am
Caris Life Sciences collects $168M to fund tumor test rollouts
Apr 9, 2025 11:51am
FDA approves Caris multi-cancer companion diagnostic test
Nov 13, 2024 9:00am
Merck KGaA signs $1.4B biobuck ADC deal with Caris
Apr 4, 2024 8:25am
JPM24: Caris crafts collabs with AbbVie, Flatiron Health
Jan 9, 2024 3:34pm
